Kathy Littrell | Head, Investor Relations |
Bruce Cozadd | Chief Executive Officer |
Renée Galá | Chief Financial Officer |
Dan Swisher | President |
Rob Iannone | Executive Vice President, R&D |
Kim Sablich | Executive Vice President, General Manager, North America |
Phil Jockelson | Neuroscience Therapeutic Head |
Ann Borgman | Hematology and Oncology Therapeutic Head |
Sam Pearce | Senior Vice President, Europe and International |
Shawn Mindus | Senior Vice President, Strategy and Finance |
Larry Carter | Global Development Lead, Neuroscience |
Brandon Folkes | Cantor Fitzgerald |
Umer Raffat | Evercore |
Gary Nachman | BMO Capital Markets |
Ami Fadia | SVB Leerink |
David Amsellem | Piper Sandler |
Ronny Gal | Bernstein |
Jason Gerberry | Bank of America |
Annabel Samimy | Stifel |
Balaji Prasad | Barclays |
Akash Tewari | Wolfe Research |
Gregg Gilbert | Truist Securities |
Jessica Fye | JPMorgan |
David Risinger | Morgan Stanley |
Graig Suvannavejh | Goldman Sachs |
David Steinberg | Jefferies |
Welcome to the Jazz Pharmaceuticals plc Third Quarter 2020 Earnings Conference Call.
Following an introduction from the company, we will open up the call to questions. I will now turn the call over to Kathy Littrell, Head of Investor Relations at Jazz Pharmaceuticals.
Thank you, Eugene [ph], and thanks to those of you joining our investor call. Today we reported our third quarter 2020 financial results and updated our financial guidance for 2020.